Full Indications
Full Indications
For certain adults with advanced non-small cell lung cancer (NSCLC)
OPDIVO® (nivolumab) is a prescription medicine used in combination with YERVOY® (ipilimumab) as a first treatment for adults with a type of advanced stage lung cancer (called non-small cell lung cancer) when your lung cancer has spread to other parts of your body (metastatic) and your tumors are positive for PD-L1, but do not have an abnormal EGFR or ALK gene.
OPDIVO® (nivolumab) is a prescription medicine used in combination with YERVOY® (ipilimumab) and 2 cycles of chemotherapy that contains platinum and another chemotherapy medicine, as a first treatment for adults with a type of advanced stage lung cancer (called non-small cell lung cancer) when your lung cancer has spread or grown, or comes back, and your tumor does not have an abnormal EGFR or ALK gene.
It is not known if OPDIVO is safe and effective in children younger than 12 years of age with melanoma or MSI-H or dMMR metastatic colorectal cancer.
It is not known if OPDIVO is safe and effective in children for the treatment of any other cancers.
OPDIVO (10 mg/mL) and YERVOY
For adults with early-stage non-small cell lung cancer (NSCLC) before surgery
OPDIVO® (nivolumab) is a prescription medicine used in combination with chemotherapy that contains platinum and another chemotherapy medicine, before you have surgery, for adults with early-stage lung cancer (called non-small cell lung cancer).
It is not known if OPDIVO is safe and effective in children younger than 12 years of age with melanoma or MSI-H or dMMR metastatic colorectal cancer.
It is not known if OPDIVO is safe and effective in children for the treatment of any other cancers.
For adults with previously treated advanced non-small cell lung cancer
OPDIVO® (nivolumab) (nivolumab) is a prescription medicine used to treat adults with a type of advanced stage lung cancer (called non-small cell lung cancer) that has spread or grown and you have tried chemotherapy that contains platinum, and it did not work or is no longer working. If your tumor has an abnormal EGFR or ALK gene, you should have also tried an FDA-approved therapy for tumors with these abnormal genes, and it did not work or is no longer working.
It is not known if OPDIVO is safe and effective in children younger than 12 years of age with melanoma or MSI-H or dMMR metastatic colorectal cancer.
It is not known if OPDIVO is safe and effective in children for the treatment of any other cancers.
For adults and children 12 years of age and older with advanced melanoma
OPDIVO® (nivolumab) is a prescription medicine used to treat adults and children 12 years of age and older with a type of skin cancer called melanoma that has spread or cannot be removed by surgery (advanced melanoma).
OPDIVO® (nivolumab) is a prescription medicine used in combination with YERVOY® (ipilimumab) to treat adults and children 12 years of age and older with a type of skin cancer called melanoma that has spread or cannot be removed by surgery (advanced melanoma).
It is not known if OPDIVO is safe and effective in children younger than 12 years of age with melanoma or MSI-H or dMMR metastatic colorectal cancer.
It is not known if OPDIVO is safe and effective in children for the treatment of any other cancers.
OPDIVO (10 mg/mL) and YERVOY
For adults and children 12 years of age and older with melanoma after it and the affected lymph nodes have been removed by surgery to prevent it from coming back
OPDIVO® (nivolumab) is a prescription medicine used to treat adults and children 12 years of age and older with a type of skin cancer called melanoma to help prevent melanoma from coming back after it and lymph nodes that contain cancer have been removed by surgery.
It is not known if OPDIVO is safe and effective in children younger than 12 years of age with melanoma or MSI-H or dMMR metastatic colorectal cancer.
It is not known if OPDIVO is safe and effective in children for the treatment of any other cancers.
For certain adults with advanced kidney cancer (renal cell carcinoma)
OPDIVO® (nivolumab) is a prescription medicine used in combination with YERVOY® (ipilimumab) to treat adults with kidney cancer in certain people when your cancer has spread (advanced renal cell carcinoma) and you have not already had treatment for your advanced RCC.
It is not known if OPDIVO is safe and effective in children younger than 12 years of age with melanoma or MSI-H or dMMR metastatic colorectal cancer.
It is not known if OPDIVO is safe and effective in children for the treatment of any other cancers.
OPDIVO (10 mg/mL) and YERVOY
For newly diagnosed adults whose kidney cancer (renal cell carcinoma) has spread
OPDIVO® (nivolumab) is a prescription medicine used in combination with cabozantinib to treat adults with kidney cancer when your cancer has spread (advanced renal cell carcinoma) and you have not already had treatment for your advanced RCC. Please read the Patient Information that comes with cabozantinib.
It is not known if OPDIVO is safe and effective in children younger than 12 years of age with melanoma or MSI-H or dMMR metastatic colorectal cancer.
It is not known if OPDIVO is safe and effective in children for the treatment of any other cancers.
For adults with previously treated advanced kidney cancer (renal cell carcinoma)
OPDIVO® (nivolumab) is a prescription medicine used to treat adults with kidney cancer (renal cell carcinoma) when your cancer has spread or grown after treatment with other cancer medications.
It is not known if OPDIVO is safe and effective in children younger than 12 years of age with melanoma or MSI-H or dMMR metastatic colorectal cancer.
It is not known if OPDIVO is safe and effective in children for the treatment of any other cancers.
For adults with previously treated squamous cell carcinoma of the head and neck
OPDIVO® (nivolumab) is a prescription medicine used to treat adults with head and neck cancer (squamous cell carcinoma) that has come back or spread and you have tried chemotherapy that contains platinum and it did not work or is no longer working.
It is not known if OPDIVO is safe and effective in children younger than 12 years of age with melanoma or MSI-H or dMMR metastatic colorectal cancer.
It is not known if OPDIVO is safe and effective in children for the treatment of any other cancers.
For adults with liver cancer (hepatocellular carcinoma) who have received treatment with sorafenib
OPDIVO® (nivolumab) is a prescription medicine used in combination with YERVOY® (ipilimumab) to treat adults with liver cancer (hepatocellular carcinoma) if you have previously received treatment with sorafenib. OPDIVO in combination with YERVOY was approved based on response rate and how long patients’ responses lasted. There is ongoing evaluation of clinical benefit of OPDIVO in combination with YERVOY for this use.
It is not known if OPDIVO is safe and effective in children younger than 12 years of age with melanoma or MSI-H or dMMR metastatic colorectal cancer.
It is not known if OPDIVO is safe and effective in children for the treatment of any other cancers.
OPDIVO (10 mg/mL) and YERVOY
For adults with previously treated advanced cancer in the bladder or urinary tract (urothelial carcinoma)
OPDIVO® (nivolumab) is a prescription medicine used to treat adults with cancer of the lining of the urinary tract (including the bladder, urethra, ureters, or renal pelvis) [urothelial carcinoma] when it has spread or grown (locally advanced or metastatic) and you have tried chemotherapy that contains platinum, and it did not work or is no longer working or your cancer worsened within 12 months of treatment with chemotherapy that contains platinum, either before or after surgery to remove your cancer.
It is not known if OPDIVO is safe and effective in children younger than 12 years of age with melanoma or MSI-H or dMMR metastatic colorectal cancer.
It is not known if OPDIVO is safe and effective in children for the treatment of any other cancers.
For adults with a type of bladder or urinary tract cancer (urothelial carcinoma) to help prevent it from coming back after it was removed by surgery
OPDIVO® (nivolumab) is a prescription medicine used to treat adults with cancer of the lining of the urinary tract (including the bladder, ureters, or renal pelvis) [urothelial carcinoma] to help prevent cancer of the urinary tract from coming back after it was removed by surgery.
It is not known if OPDIVO is safe and effective in children younger than 12 years of age with melanoma or MSI-H or dMMR metastatic colorectal cancer.
It is not known if OPDIVO is safe and effective in children for the treatment of any other cancers.
For people 12 years of age and older whose CRC has spread to other parts of the body (metastatic); has progressed after treatment with a fluoropyrimidine, oxaliplatin, and irinotecan; and is MSI-H or dMMR
OPDIVO® (nivolumab) is a prescription medicine used in combination with YERVOY® (ipilimumab) to treat adults and children 12 years of age and older, with a type of colon or rectal cancer (colorectal cancer) that has spread to other parts of the body (metastatic), is microsatellite instability-high (MSl-H) or mismatch repair deficient (dMMR), and you have tried treatment with a fluoropyrimidine, oxaliplatin, and irinotecan, and it did not work or is no longer working. OPDIVO in combination with YERVOY was approved based on response rate and how long patients' responses lasted. There is ongoing evaluation of clinical benefit of OPDIVO in combination with YERVOY for this use.
OPDIVO (10 mg/mL) and YERVOY
OPDIVO® (nivolumab) is a prescription medicine used to treat adults and children 12 years of age and older with a type of colon or rectal cancer (colorectal cancer) that has spread to other parts of the body (metastatic), is microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR), and you have tried treatment with a fluoropyrimidine, oxaliplatin, and irinotecan, and it did not work or is no longer working. OPDIVO was approved based on response rate and how long patients' responses lasted. There is ongoing evaluation of clinical benefit of OPDIVO for this use.
It is not known if OPDIVO is safe and effective in children younger than 12 years of age with melanoma or MSI-H or dMMR metastatic colorectal cancer.
It is not known if OPDIVO is safe and effective in children for the treatment of any other cancers.
For adults with previously treated classical Hodgkin lymphoma including an autologous stem cell transplant whose cancer has come back or spread
OPDIVO® (nivolumab) is a prescription medicine used to treat adults with a type of blood cancer called classical Hodgkin lymphoma if your cancer has come back or spread after a type of stem cell transplant that uses your own stem cells (autologous), and you used the medicine brentuximab vedotin before or after your stem cell transplant, or if you received at least 3 kinds of treatment including an autologous stem cell transplant. OPDIVO was approved based on response rate. There is ongoing evaluation of clinical benefit of OPDIVO for this use.
It is not known if OPDIVO is safe and effective in children younger than 12 years of age with melanoma or MSI-H or dMMR metastatic colorectal cancer.
It is not known if OPDIVO is safe and effective in children for the treatment of any other cancers.
For adults with previously treated advanced esophageal squamous cell cancer
OPDIVO® (nivolumab) is a prescription medicine used to treat adults with cancer of the tube that connects your throat to your stomach (esophageal cancer) if your esophageal cancer is a type called squamous cell carcinoma, and cannot be removed with surgery, and has come back or spread to other parts of the body after you have received chemotherapy that contains fluoropyrimidine and platinum.
It is not known if OPDIVO is safe and effective in children younger than 12 years of age with melanoma or MSI-H or dMMR metastatic colorectal cancer.
It is not known if OPDIVO is safe and effective in children for the treatment of any other cancers.
For adults newly diagnosed with malignant pleural mesothelioma (MPM)
OPDIVO® (nivolumab) is a prescription medicine used in combination with YERVOY® (ipilimumab) as a first treatment for adults with a type of cancer that affects the lining of the lungs and chest wall called malignant pleural mesothelioma which cannot be removed by surgery.
It is not known if OPDIVO is safe and effective in children younger than 12 years of age with melanoma or MSI-H or dMMR metastatic colorectal cancer.
It is not known if OPDIVO is safe and effective in children for the treatment of any other cancers.
OPDIVO (10 mg/mL) and YERVOY
For adults with esophageal or gastroesophageal junction (GEJ) cancer who have been treated with chemoradiation followed by surgery to help prevent it from coming back
OPDIVO® (nivolumab) is a prescription medicine that may be used in adults to help prevent cancer of the tube that connects your throat to your stomach (esophageal cancer) or cancer where the esophagus joins the stomach (gastroesophageal junction cancer) from coming back after it has been treated with chemoradiation followed by surgery to remove the cancer, but some cancer cells were still present in the removed tumor or lymph nodes.
It is not known if OPDIVO is safe and effective in children younger than 12 years of age with melanoma or MSI-H or dMMR metastatic colorectal cancer.
It is not known if OPDIVO is safe and effective in children for the treatment of any other cancers.
For previously untreated adults with advanced or metastatic esophageal squamous cell cancer (ESCC)
OPDIVO® (nivolumab) is a prescription medicine used in combination with chemotherapy that contains fluoropyrimidine and platinum to treat adults with cancer of the tube that connects your throat to your stomach (esophageal cancer) when your cancer is a type called squamous cell carcinoma and cannot be removed with surgery (advanced) or has spread to other parts of the body (metastatic) and you have not already had treatment for your advanced or metastatic esophageal cancer.
OPDIVO® (nivolumab) is a prescription medicine used in combination with YERVOY® (ipilimumab) to treat adults with cancer of the tube that connects your throat to your stomach (esophageal cancer) when your cancer is a type called squamous cell carcinoma and cannot be removed with surgery (advanced) or has spread to other parts of the body (metastatic), and you have not already had treatment for your advanced or metastatic esophageal cancer.
It is not known if OPDIVO is safe and effective in children younger than 12 years of age with melanoma or MSI-H or dMMR metastatic colorectal cancer.
It is not known if OPDIVO is safe and effective in children for the treatment of any other cancers.
For certain previously untreated adults with advanced gastric, gastroesophageal junction, and esophageal adenocarcinomas
OPDIVO® (nivolumab) is a prescription medicine used in combination with chemotherapy that contains fluoropyrimidine and platinum to treat adults with cancer of the stomach (gastric), junction between the stomach and esophagus (gastroesophageal junction), and esophagus that is a type called adenocarcinoma and cannot be removed with surgery or has spread to other parts of the body.
It is not known if OPDIVO is safe and effective in children younger than 12 years of age with melanoma or MSI-H or dMMR metastatic colorectal cancer.
It is not known if OPDIVO is safe and effective in children for the treatment of any other cancers.
Explore Treatment With OPDIVO and
OPDIVO-based Combinations
Every patient or family member has a story to tell. Below are videos created to help you learn more about treatment with
OPDIVO and OPDIVO-based combinations, including real patient experiences, how treatment works, and family
members who share their experience and treatment journey.
John’s Story
OPDIVO for Adults Who Have Had Prior Treatments for Non-Small Cell Lung Cancer
John is a husband, father of two, and a passionate golfer. Learn more about his experience with OPDIVO. (14:10)
For more information, see OPDIVO NSCLC clinical trial results.
Dave’s story
OPDIVO® + YERVOY® (ipilimumab) for Newly Diagnosed Advanced Melanoma
Dave is a restaurant owner and father. Three different doctors agreed that OPDIVO + YERVOY was the right choice for him. (20:03)
For more information, see OPDIVO + YERVOY metastatic melanoma clinical trial results.
OPDIVO for Adults Who Have Had Prior Treatments for Non-Small Cell Lung Cancer
John is a husband, father of two, and a passionate golfer. Learn more about his experience with OPDIVO. (14:10)
OPDIVO will not work for everyone.
Individual results may vary.
PATIENTS AND CAREGIVERS
View additional materials you or your loved one may find helpful, including information on support materials, questions to ask your doctor, and other patient resources.
SIGN UP FOR
Complimentary support, tools,
and educational resources for
anyone considering or currently
taking OPDIVO.
Call 1-855-OPDIVO-1 or
click to learn more.
OPDIVO + YERVOY® (ipilimumab) for Newly Diagnosed Advanced Melanoma
Dave is a restaurant owner and father. Three different doctors agreed that OPDIVO + YERVOY was the right choice for him. (20:03)
OPDIVO and YERVOY will not work for everyone. Individual results may vary.
PATIENTS AND CAREGIVERS
View additional materials you or your loved one may find helpful, including information on support materials, questions to ask your doctor, and other patient resources.
SIGN UP FOR
Complimentary support, tools,
and educational resources for
anyone considering or currently
taking OPDIVO.
Call 1-855-OPDIVO-1 or
click to learn more.
CAROL’S STORY
OPDIVO + YERVOY for Certain Newly Diagnosed Adults With Advanced Kidney Cancer
After Carol was diagnosed, she spoke with her doctor about immunotherapy options. Together, they decided to start treatment with OPDIVO + YERVOY. (18:17)
For more information, see OPDIVO + YERVOY RCC clinical trial results.
Terry’s Story
OPDIVO for Adults With Previously Treated Squamous Cell Carcinoma of the Head and Neck
Terry’s cancer kept returning with radiation and a platinum-based therapy. Learn more about his treatment with OPDIVO. (11:26)
For more information, see OPDIVO SCCHN clinical trial results.
OPDIVO + YERVOY for Certain Newly Diagnosed Adults With Advanced Kidney Cancer
After Carol was diagnosed, she spoke with her doctor about immunotherapy options. Together, they decided to start treatment with OPDIVO + YERVOY. (18:17)
OPDIVO and YERVOY will not work for everyone. Individual results may vary.
PATIENTS AND CAREGIVERS
View additional materials you or your loved one may find helpful, including information on support materials, questions to ask your doctor, and other patient resources.
SIGN UP FOR
Complimentary support, tools,
and educational resources for
anyone considering or currently
taking OPDIVO.
Call 1-855-OPDIVO-1 or
click to learn more.
OPDIVO for Adults With Previously Treated Squamous Cell Carcinoma of the Head and Neck
Terry’s cancer kept returning with radiation and a platinum-based therapy. Learn more about his treatment with OPDIVO. (11:26)
OPDIVO will not work for everyone. Individual results may vary.
PATIENTS AND CAREGIVERS
View additional materials you or your loved one may find helpful, including information on support materials, questions to ask your doctor, and other patient resources.
SIGN UP FOR
Complimentary support, tools,
and educational resources for
anyone considering or currently
taking OPDIVO.
Call 1-855-OPDIVO-1 or
click to learn more.
John’S story
OPDIVO + YERVOY for Certain Newly Diagnosed Adults with Advanced Non-Small Cell Lung Cancer That Tests Positive for PD-L1
John is a Navy veteran and a father of four who loves to travel. Find out more about John, a patient who received OPDIVO + YERVOY, and his experience being diagnosed with advanced lung cancer. (3:04)
For more information, see OPDIVO + YERVOY NSCLC clinical trial results.
JOHN & HIS NURSE JILLIAN
An Oncology Nurse and Her Patient’s Treatment Journey
Living with cancer can be challenging. Watch an oncology nurse and one of her patients share their experience with OPDIVO + YERVOY. While everyone’s cancer journey is different, they hope this video series may help others with their own cancer journey.
OPDIVO + YERVOY for Certain Adults With Advanced Non-Small Cell Lung Cancer That Tests Positive for PD-L1
John is a Navy veteran and a father of four who loves to travel. Find out more about John, a patient who received OPDIVO + YERVOY, and his experience being diagnosed with advanced lung cancer. (3:04)
OPDIVO will not work for everyone. Individual results may vary.
PATIENTS AND CAREGIVERS
View additional materials you or your loved one may find helpful, including information on support materials, questions to ask your doctor, and other patient resources.
SIGN UP FOR
Complimentary support, tools,
and educational resources for
anyone considering or currently
taking OPDIVO.
Call 1-855-OPDIVO-1 or
click to learn more.
An Oncology Nurse and Her Patient’s Treatment Journey
Living with cancer can be challenging. Watch an oncology nurse and one of her patients share their experience with OPDIVO + YERVOY. While everyone’s cancer journey is different, they hope this video series may help others with their own cancer journey.
OPDIVO and YERVOY will not work for everyone. Individual results may vary.
PATIENTS AND CAREGIVERS
View additional materials you or your loved one may find helpful, including information on support materials, questions to ask your doctor, and other patient resources.
SIGN UP FOR
Complimentary support, tools,
and educational resources for
anyone considering or currently
taking OPDIVO.
Call 1-855-OPDIVO-1 or
click to learn more.
Rob’s story
OPDIVO + Chemotherapy for Previously Untreated Patients with Advanced Gastric Cancer, Gastroesophageal Junction Cancer, or Esophageal Cancer
Rob is a husband, father of two, and former coach for kids' sports teams. See how he, his wife, and his doctor made a game plan with OPDIVO + chemotherapy for advanced esophageal cancer. (20:29)
For more information, see OPDIVO + chemotherapy GI clinical trial results.
Roberto’s story
OPDIVO + YERVOY for Newly Diagnosed Advanced Melanoma
Roberto is a self-made business owner and avid painter from Puerto Rico. Join him on his journey from the moment of his diagnosis of advanced melanoma to his treatment with OPDIVO + YERVOY. (19:03)
For more information, see OPDIVO + YERVOY metastatic melanoma clinical trial results.
OPDIVO + Chemotherapy for Previously Untreated Patients with Advanced Gastric Cancer, Gastroesophageal Junction Cancer, or Esophageal Cancer
Rob is a husband, father of two, and former coach for kids' sports teams. See how he, his wife, and his doctor made a game plan with OPDIVO + chemotherapy for advanced esophageal cancer. (3:04)
OPDIVO will not work for everyone. Individual results may vary.
PATIENTS AND CAREGIVERS
View additional materials you or your loved one may find helpful, including information on support materials, questions to ask your doctor, and other patient resources.
SIGN UP FOR
Complimentary support, tools,
and educational resources
for
anyone considering or currently
taking OPDIVO.
Call
1-855-OPDIVO-1 or
click to learn more.
OPDIVO + YERVOY for Newly Diagnosed Advanced Melanoma
Roberto is a self-made business owner and avid painter from Puerto Rico. Join him on his journey from the moment of his diagnosis of advanced melanoma to his treatment with OPDIVO + YERVOY. (19:03)
OPDIVO will not work for everyone. Individual results may vary.
PATIENTS AND CAREGIVERS
View additional materials you or your loved one may find helpful, including information on support materials, questions to ask your doctor, and other patient resources.
SIGN UP FOR
Complimentary support, tools,
and educational resources for
anyone considering or currently
taking OPDIVO.
Call 1-855-OPDIVO-1 or
click to learn more.
Would you like to share your story?
If you or a loved one is interested in sharing your experience on an OPDIVO treatment, please call
1-855-436-5866.
All patients were compensated for their time in the creation of these videos.
MARCIA AND JOHN’S STORY
OPDIVO + YERVOY for Certain Newly Diagnosed Adults with Advanced Non-Small Cell Lung Cancer That Tests Positive for PD-L1
Marcia is the matriarch of her family of four. Find out more about her experience becoming a caregiver to her younger brother, John, after he was suddenly diagnosed with advanced lung cancer and began receiving OPDIVO. (3:23)
For more information, see OPDIVO + YERVOY NSCLC clinical trial results.
OPDIVO + YERVOY for Certain Newly Diagnosed Adults with Advanced Non-Small Cell Lung Cancer That Tests Positive for PD-L1
Marcia is the matriarch of her family of four. Find out more about her experience becoming a caregiver to her younger brother, John, after he was suddenly diagnosed with advanced lung cancer and began receiving OPDIVO (3:23)
OPDIVO and YERVOY will not work for everyone. Individual results may vary.
PATIENTS AND CAREGIVERS
View additional materials you or your loved one may find helpful, including information on support materials, questions to ask your doctor, and other patient resources.
SIGN UP FOR
Complimentary support, tools,
and educational resources for
anyone considering or currently
taking OPDIVO.
Call 1-855-OPDIVO-1 or
click to learn more.
All patients were compensated for their time in the creation of these videos.
TV COMMERCIAL
OPDIVO + YERVOY for Advanced NSCLC
Discover a treatment option for certain adults with newly diagnosed advanced non-small cell lung cancer (NSCLC) that tests positive for PD-L1. (1:30)
OPDIVO + YERVOY VIDEO
OPDIVO + YERVOY for Advanced Kidney Cancer
Discover a treatment option for certain people newly diagnosed with advanced kidney cancer. (2:23)
patients younger than 18 years of age.
OPDIVO + YERVOY for Advanced NSCLC
Discover a treatment option for certain adults with newly diagnosed advanced non-small cell lung cancer (NSCLC) that tests positive for PD-L1. (1:30)
OPDIVO and YERVOY will not work for everyone. Individual results may vary.
PATIENTS AND CAREGIVERS
View additional materials you or your loved one may find helpful, including information on support materials, questions to ask your doctor, and other patient resources.
SIGN UP FOR
Complimentary support, tools,
and educational resources for
anyone considering or currently
taking OPDIVO.
Call 1-855-OPDIVO-1 or
click to learn more.
OPDIVO + YERVOY for Advanced Kidney Cancer
Discover a treatment option for certain people newly diagnosed with advanced kidney cancer. (2:23)
OPDIVO and YERVOY will not work for everyone. Individual results may vary.
PATIENTS AND CAREGIVERS
View additional materials you or your loved one may find helpful, including information on support materials, questions to ask your doctor, and other patient resources.
SIGN UP FOR
and educational resources for
anyone considering or currently
taking OPDIVO.
Call
1-855-OPDIVO-1 or
click to learn more.
OPDIVO + YERVOY VIDEO
OPDIVO + YERVOY for Advanced Melanoma
Discover a treatment option for newly diagnosed adults with advanced melanoma. (2:25)
Patient Resources
OPDIVO with You
Get complimentary support, tools, and educational resources with the OPDIVO with You Program. (3:30)
OPDIVO + YERVOY for Advanced Melanoma
Discover a treatment option for newly diagnosed adults with advanced melanoma. (2:25)
OPDIVO and YERVOY will not work for everyone. Individual results may vary.
PATIENTS AND CAREGIVERS
View additional materials you or your loved one may find helpful, including information on support materials, questions to ask your doctor, and other patient resources.
SIGN UP FOR
Complimentary support, tools,
and educational resources
for
anyone considering or currently
taking OPDIVO.
Call
1-855-OPDIVO-1 or
click to learn more.
OPDIVO with You
Get complimentary support, tools, and educational resources with the OPDIVO with You Program. (3:30)
OPDIVO will not work for everyone. Individual results may vary.
PATIENTS AND CAREGIVERS
View additional materials you or your loved one may find helpful, including information on support materials, questions to ask your doctor, and other patient resources.
SIGN UP FOR
Complimentary support, tools,
and educational resources
for
anyone considering or currently
taking OPDIVO.
Call
1-855-OPDIVO-1 or
click to learn more.
How OPDIVO + YERVOY WORKS
How OPDIVO + YERVOY Works
Discover how this combination immunotherapy treatment can work with your immune system. (2:08)
How OPDIVO Works
How OPDIVO Works
Discover how this immunotherapy treatment can work with your immune system. (1:13)
How OPDIVO + YERVOY Works
Discover how this combination immunotherapy treatment can work with your immune system. (2:08)
OPDIVO and YERVOY will not work for everyone. Individual results may vary.
PATIENTS AND CAREGIVERS
View additional materials you or your loved one may find helpful, including information on support materials, questions to ask your doctor, and other patient resources.
SIGN UP FOR
Complimentary support, tools,
and educational resources
for
anyone considering or currently
taking OPDIVO.
Call
1-855-OPDIVO-1 or
click to learn more.
How OPDIVO Works
Discover how this immunotherapy treatment can work with your immune system. (1:13)
OPDIVO will not work for everyone. Individual results may vary.
PATIENTS AND CAREGIVERS
View additional materials you or your loved one may find helpful, including information on support materials, questions to ask your doctor, and other patient resources.
SIGN UP FOR
Complimentary support, tools,
and educational resources
for
anyone considering or currently
taking OPDIVO.
Call
1-855-OPDIVO-1 or
click to learn more.
OPDIVO WITH YOU SUPPORT PROGRAM
Lisa’s Story
Watch Lisa, an OPDIVO patient, talk about her experience with OPDIVO with You. (2:18)
Lisa’s Story
Watch Lisa, an OPDIVO patient, talk about her experience with OPDIVO with You. (2:18)
OPDIVO will not work for everyone. Individual results may vary.
PATIENTS AND CAREGIVERS
View additional materials you or your loved one may find helpful, including information on support materials, questions to ask your doctor, and other patient resources.
SIGN UP FOR
Complimentary support, tools,
and educational resources
for
anyone considering or currently
taking OPDIVO.
Call
1-855-OPDIVO-1 or
click to learn more.
SIGN UP FOR
Complimentary support, tools,
and educational resources
for
anyone considering or currently
taking OPDIVO.
Call
1-855-OPDIVO-1 or
click to learn more.
